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Medium-chain triglyceride (MCT) ketogenic diets increase ketone bodies, which are believed 
to act as alternative energy substrates in the injured brain. Octanoic (C8:0) and decanoic 
(C10:0) acids, which produce ketone bodies through β-oxidation, are used as part of MCT 
ketogenic diets. Although the ketogenic role of MCT is well-established, it remains unclear 
how the network metabolism underlying β-oxidation of these medium-chain fatty acids 
(MCFA) differ. We aim to elucidate basal β-oxidation of these commonly used MCFA at the 
cellular level. Human-induced pluripotent stem cell-derived (iPSC) astrocytes were incubated 
with [U-13C]-C8:0 or [U-13C]-C10:0, and the fractional enrichments (FE) of the derivatives 
were used for metabolic flux analysis. Data indicate higher extracellular concentrations 
and faster secretion rates of β-hydroxybutyrate (βHB) and acetoacetate (AcAc) with C8:0 
than C10:0, and an important contribution from unlabeled substrates. Flux analysis indicates 
opposite direction of metabolic flux between the MCFA intermediates C6:0 and C8:0, with 
an important contribution of unlabeled sources to the elongation in the C10:0 condition, 
suggesting different β-oxidation pathways. Finally, larger intracellular glutathione 
concentrations and secretions of 3-OH-C10:0 and C6:0 were measured in C10:0-treated 
astrocytes. These findings reveal MCFA-specific ketogenic properties. Our results provide 
insights into designing different MCT-based ketogenic diets to target specific health benefits.
Keywords: β-oxidation, 13C-metabolic flux analysis, decanoic acid, induced pluripotent stem cell-derived 
astrocytes, octanoic acid
INTRODUCTION
Medium chain triglyceride-based (MCT) ketogenic diets are currently proposed as alternative 
brain energy substrates in conditions of limited cerebral glucose availability, such as in traumatic 
brain injury (TBI) (Prins and Matsumoto, 2014; Bernini et  al., 2018), patients with glucose 
transporter 1 deficiency (Krass et al., 2016) and Alzheimer’s disease (Reger et al., 2004; Castellano 
et  al., 2015; Cunnane et  al., 2016; Croteau et  al., 2018). Moreover, besides having antioxidant 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
49
55
 
| 
do
wn
lo
ad
ed
: 
4.
12
.2
01
9
Sonnay et al. Metabolism of MCFA in Astrocytes
Frontiers in Physiology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 657
properties (Jarrett et  al., 2008), ketogenic diets were reported 
to be important in seizure control in epileptic patients (Pulford, 
1927; Neal et al., 2008). MCTs are glycerolesters usually carrying 
a mixture of octanoic (C8:0) and decanoic (C10:0) acid. Yet, 
the rationale behind the selection of C8:0 and C10:0 is unclear. 
Upon supplementation, MCT are hydrolyzed in the gut, which 
leads to an increase in the plasma concentrations of the medium 
chain fatty acids (MCFA) (i.e., C8:0 and C10:0) (Bernini et  al., 
2018). In the brain, MCFA cross the blood-brain barrier (Wlaź 
et  al., 2015) and are oxidized in cells (Ebert et  al., 2003) 
through β-oxidation for acetyl-CoA (AcCoA) generation and 
subsequent production of ketone bodies (Auestad et  al., 1991), 
namely β-hydroxybutyrate (βHB) and acetoacetate (AcAc). 
Those produced ketone bodies can further be used as metabolic 
fuel by the brain (Nugent et  al., 2014; Andersen et  al., 2017; 
Evans et  al., 2017).
While astrocytes have been restricted to a scaffold-associated 
function in the brain for decades, new lines of evidence suggest 
the important role of astrocytic oxidative metabolism for 
supporting brain function (Sonnay et  al., 2016, 2017, 2018), 
as well as the preferential stimulation of astrocytic metabolism 
by fatty acids, and subsequent ketone bodies production 
(Edmond et  al., 1987; Thevenet et  al., 2016).
Based on our initial observations (Thevenet et  al., 2016) 
and although C10:0 and C8:0 differ in length by only two 
carbons, we  hypothesize that they differ in their ability to 
contribute to ketogenesis. In astrocytes, the metabolic pathways 
giving rise to ketone bodies remain unclear (Thevenet et  al., 
2016) and new insights into astrocytic ketogenesis and 
β-oxidation may help to define the optimal MCFA composition 
of the ketogenic diets. We have recently observed a significant 
but modest increase in plasma C8:0 and C10:0  in the subset 
of TBI patients after receiving high level MCT enteral nutrition 
(Bernini et  al., 2018). Interestingly, administration of higher 
MCT concentrations, compared to commonly used formula, 
did not have significant impact on the level of ketones 
produced. This further confirms the importance of identifying 
the optimal formulation to raise brain ketones to therapeutically 
relevant levels.
Therefore, we  investigated β-oxidation of C8:0 and C10:0 
to assess the underlying metabolic network, differences in 
metabolic flux pathways and ketogenesis at the basal level. 
We  aimed to provide insights into the production of ketones 
in the brain and potential differences in metabolic properties 
of MCFA, namely differential secretions of MCFA intermediates 
and glutathione formation. Using our established cellular 
model (Thevenet et  al., 2016), we  tracked the metabolism 
of [U-13C]-C8:0 and [U-13C]-C10:0  in differentiated human-
induced pluripotent stem cell-derived (iPSC) astrocytes by 
using liquid chromatography-mass spectrometry (LC-MS), 
conducted an integrated analysis in silico to identify and 
characterize specific reactions leading to the production of 
βHB, and formulated a reduced (sub-network) astrocyte-
specific mathematical model of β-oxidation that was fitted 
to the experimental data (Figure 1A). The results indicate 
significant differences in MCFA metabolism. In particular, 
astrocytes incubated with C8:0 release βHB, AcAc and butyrate 
in larger amounts and at higher rates than with C10:0, with 
the major fraction coming from unlabeled substrates 
(irrespectively of the initial MCFA). Moreover, flux analysis 
indicates opposite direction of metabolic flux between the 
MCFA intermediates C8:0 and C6:0, with an important fraction 
of unlabeled sources contributing to the elongation steps in 
the case of C10:0, suggesting different β-oxidation pathways. 
Finally, larger intracellular glutathione concentrations, 
indicating potential additional antioxidant benefits, as well 
as higher secretions of 3-OH-C10:0 and C6:0 were measured 
in C10:0-treated astrocytes. Overall, these findings suggest 
C8:0- and C10:0-specific ketometabolic traits relevant for 
further studies on designing optimal ketogenic nutritional 
interventions using appropriate C8:0/C10:0 ratios to reach 
specific health benefits.
MATERIALS AND METHODS
Chemicals and Reagents
Acetonitrile, ethanol, and isopropanol (LC-MS grade) were 
purchased from VWR Internationals (Leuven, Belgium) and 
Merck (Darmstadt, Germany). Water was purified in-house 
using a Milli-Q Advantage A10 system from Merck Millipore 
(Billerica, MA, USA). Acetic acid was supplied by Sigma-Aldrich 
(St. Louis, MO, USA). Chemicals used for internal and external 
calibration were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), Larodan (Solna, Sweden), Toronto Research Chemical 
(Toronto, Canada), CDN Isotopes Inc. (Pointe-Claire, Canada), 
and Cambridge Isotopes Laboratories (Tewksbury, MA, USA). 
Uniformly labeled tracers 13C8-octanoic acid [>99% 13C, [U-13C]-
C8:0] and 13C10 decanoic acid [>98% 13C, [U-13C]-C10:0] were 
purchased from Cambridge Isotopes Laboratories (Tewksbury, 
MA, USA). Stocks of [U-13C]-C8:0 and [U-13C]-C10:0 were 
prepared in dimethyl sulfoxide (DMSO) at 100  mM with 0.3% 
DMSO final concentration.
Liquid Chromatographic Separation and 
Mass Spectrometric Detection
Liquid chromatography was performed on a I-Class UPLC 
system (Waters Corporation, Milford, MA, USA) combining 
a binary pump, a FTN autosampler and a column oven. 
Chromatographic separation was achieved on a Waters ACQUITY 
UPLC BEH C8 Column (100  mm × 2.1  mm, 1.7  μm) with 
binary solvent system at a flow rate of 450  μl/min. Mobile 
phase A was 0.1% acetic acid in water and B was 0.1% acetic 
acid in acetonitrile/isopropanol (1:1). The binary solvent gradient 
was as follow: 0.0–1.0  min at 0% B, 1.0–6.5  min from 0 to 
100% B, 6.5–8.5 min 100% B, followed by 2 min of equilibration 
Abbreviations: AcAc, Acetoacetate; AcCoA, Acetyl-CoA; ACP, Acyl-carrier protein; 
AMPA, α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AUC, Area under 
the curve; βHB, β-Hydroxybutyrate; FE, Fractional enrichment; HMG, 3-Hydroxy-
3-methyl glutarate; iPSC, Induced pluripotent stem cell-derived; LC-MS, Liquid-
chromatography mass spectrometry; MC, Monte Carlo; MCFA, Medium-chain fatty 
acid; MCT, Medium-chain triglyceride; MS, Mass spectrometry; TBI, Traumatic 
brain injury.
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at initial conditions. Column oven temperature was set to 55°C 
and the autosampler injection volume to 1  μl.
High resolution mass spectrometric analysis was performed 
on a Q Exactive mass spectrometer (ThermoFisher Scientific, 
Bremen, Germany) operating in negative ionization mode 
over the mass range m/z 65–600 with a resolving power of 
70,000 (at m/z  =  200). Data was acquired in profile mode 
with an AGC target of 5e6 ions and a maximum injection 
time of 250  ms. The mass spectrometer was interfaced to 
the UPLC system using a HESI probe. The spray voltage was 
set to −4  kV. The heater and capillary temperatures were 
both set to 350°C. Sheath gas and auxiliary gas flow rate 
were set to 45 and 15  AU, respectively. The instrument was 
calibrated every 4 days according to manufacturer specifications.
Cell Culture
All experiments were approved by the Swiss Ethics Committees 
on Research Involving Humans. Differentiated human iPSCs 
(iCell astrocytes) were obtained from Cellular Dynamics 
International (CDI, Madison, WI, USA). The cells were thawed 
A
B C
D
FIGURE 1 | (A) Overview of the experimental set-up and study design. Human iPSC astrocytes were treated with [U-13C]-C8:0 or [U-13C]-C10:0. Supernatants and 
cell monolayers were collected at 0, 5, 30, 60, 120, 240, and 360 min, and analyzed by LC-MS. MCFA intermediates involved in β-oxidation and ketone bodies 
production were quantified. Analysis of C8:0 and C10:0 metabolism in silico was performed, and a mathematical (sub-network) based on the latter and on the 
detected metabolites was built to fit the experimental 13C isotopomer FE curves. The resulting fluxes were compared between conditions. (B) Secretion rates and 
AUC of selected ketone bodies, HMG and butyrate determined from the total extracellular concentrations experimentally measured. (C) Changes in mass 
isotopomer concentrations of ketone bodies, HMG and butyrate measured in the medium over time for the C8:0 and C10:0 experiments. (D) Secretion rates and 
AUC determined from experimentally measured extracellular concentrations for each mass isotopomer (C). **p < 0.01; ***p < 0.001.
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according to the manufacturer’s instruction. iPSC astrocytes 
were cultured in DMEM containing 25  mM glucose, 
1 mM pyruvate, and 4 mM glutamine (Thermo Scientific-Life 
Technologies, ref. 41966029) supplemented with 10% fetal 
calf serum and N2 complement. Cells were kept in culture 
in a humidified atmosphere (5% CO2) at 37°C for 7  days 
with medium changed at days 3 and 6.
Sample Preparation
A 0.1–0.5  μM internal standard solution was prepared by 
mixing individual stock solutions with mobile phase A. This 
solution contained heavy labeled compounds, which do not 
interfere with measured isotopomers and was used to dilute 
media samples and reconstitute cell extracts.
Cells were prepared as previously described (Thevenet et al., 
2016). Briefly, iPSC astrocytes were washed three times and 
incubated in serum- and glutamine- free DMEM A14430-01 
(Thermo Scientific-Life Technologies) containing 1 mM glucose, 
N2 supplement, and 300  μM [U-13C]-C8:0 or [U-13C]-C10:0 
for up to 6  h (1  ml/well). Experiments were run in duplicates 
in three independent experiments (n  =  3). Cell supernatant 
was collected at different time points (0, 5, 10, 30, 60, 120, 
240, and 360  min) and stored at −80°C until analysis. On 
analysis day, 25  μl of cell culture supernatant was mixed with 
25 μl of dilution solution (50 μl internal standard stock solution 
diluted with 450  μl mobile phase A) in a PCR plate. The 
plate was sealed, placed in a Thermomixer Comfort C maintained 
at 4°C, and shaken for 5  min at 1,000  rpm. Samples were 
placed in the autosampler and immediately analyzed.
Cell monolayers were collected at different time points 
(0, 5, 10, 30, 60, 120, 240, and 360  min). At each time point, 
cells were immediately placed on ice to stop metabolism, washed 
with cold PBS, and frozen. After collection, cell pellets were 
extracted once with 500 μl and once with 700 μl ethanol/water 
(7:3) followed by centrifugation at 17,500  g for 20  min. 
Supernatants were dried under vacuum at room temperature 
and the solid residues were reconstituted in 30  μl of mobile 
phase A and immediately analyzed. The pellets were stored 
at −80°C until protein content quantification.
Protein Content
Protein content was determined with a bicinchoninic acid-based 
protein assay (BCA protein assay kit 10678484; Thermo Scientific) 
with bovine serum albumin as standard.
Biochemical Pathway Analysis
The objectives of this analysis were to identify astrocyte-specific 
metabolic intermediates and metabolic routes of C8:0-C10:0 
to βHB transformation including key intermediates (e.g., 
AcCoA, AcAc and 3-Hydroxy-3-methyl glutarate (HMG)). This 
consisted of two steps. The first step was the enumeration 
of paths from compound of interest (i.e., C8:0-C10:0) and 
target of interest (i.e., βHB). In this regard, we  used the 
KEGG database (Kanehisa and Goto, 2000; Kanehisa et  al., 
2016, 2017) and specifically, the PathComp methodology (Goto 
et  al., 1997) to identify the human-specific metabolic paths 
between the compounds of interest. We  limited the search 
of paths to a maximum length of 20 (i.e., 20 biochemical 
transformations from the starting compound). The second 
step was the refinement of the transformations identified in 
step one based on genome scale metabolic models (i.e., astrocyte 
specificity) (Schultz and Cutub, 2016). In this regard, we used 
the astrocyte-neuronal metabolic model published by Özcan 
and Çakır (2016). The model provided curated astrocyte-specific 
metabolic information for 276 metabolites interacting across 
375 reactions. Out of the metabolites and reactions participating 
in the paths identified in the first step, only those implicated 
in the astrocyte model were considered for further analysis.
Network analysis and visualization of paths, interconnectivities, 
and cellular specificities were performed using custom Matlab 
(Mathwork Inc.) scripts and edited using yEd (yWorks GmbH).
Modeling of Experimental 13C Curves
Chromatogram extraction using a mass tolerance of 5  ppm 
and calculation of ratios of mass isotopomers to internal standard 
were performed in Xcalibur Software 2.2 SP1. Absolute 
concentrations were calculated by multiplying the area ratio 
by the internal standard amount. Time-course data (cells and 
media) were subtracted to initial conditions (i.e., cells and 
media before incubation, respectively) and normalized to protein 
content. Similar procedure was performed in an unrelated cell 
line (i.e., HepG2 cells) under similar experimental conditions 
for astrocytic-specificity measurements validation. Key 
metabolites are reported in Supplementary Figure S1. Then, 
correction for substrate purity and natural abundance of the 
isotope, and calculation of fractional enrichments (FE) were 
performed with IsoCor Software 1.0 (Millard et  al., 2012). 
Mass isotopomers differ by the number of 13C atoms in the 
molecule. C0 represents the fraction of unlabeled molecules 
in the total molecule pool, C1 the fraction of molecules 
labeled in one carbon, C2  in two carbons, etc. The sum of 
all fractions is one.
Isotopic transient 13C-metabolic flux analysis of [U-13C]-C8:0 
and [U-13C]-C10:0 through β-oxidation was based on the 
intracellular and extracellular detection of the derivative 
metabolites. FE  <  1% were not considered in the modeling 
process, because they were associated with large uncertainty. 
The metabolic model describing 13C labeling was solved 
mathematically by a set of linear differential mass isotopomer-
balance equations describing the stoichiometry of the system 
at equilibrium and assuming negligible cellular growth 
(Supplementary Data). Metabolic steady-state and isotopic 
transient-state were considered during the experiment, as 
during incubation of the labeled substrate, the total intracellular 
pools of free acids remained unchanged and the distribution 
of mass isotopomers changed with time according to the 
flux network. The model was fitted to the experimental 
measurements by minimizing the residual sum of squares 
using least square regression. Variance of the estimated fluxes 
was calculated with Monte Carlo (MC) simulations using 
artificially generated dataset by adding Gaussian noise with 
similar variance of the fit residuals to the best fit. Initial 
values were randomly generated within confidence interval 
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of the obtained fluxes. All numerical procedures were performed 
in Matlab (Mathwork Inc.).
All pool sizes were determined from the LC-MS measurements, 
except the pool of AcCoA, whose value was set to 0.027 μmol/mg 
prot (Amaral et  al., 2011). As extracellular metabolite 
concentrations increased over time, net specific transmembrane 
rates were calculated experimentally from the slope of a linear 
regression to those changes. The resulting values were fixed 
in the modeling process.
Statistics
Data are shown as mean ± SD. For experimental measurements, 
the SD was determined from three independent experiments, 
which were run in duplicate. For metabolic fluxes, the SD 
was determined from fitting a Gamma function to the histograms 
obtained from at least 500 MC. Flux comparison between C8:0 
an C10:0 experiments was performed by permutation analysis 
with 2000 permutations followed by individual two-tailed student 
t-test. Experimental measurements comparison between C8:0 
and C10:0 experiments was also performed by individual 
two-tailed student t-test. All reported p’s were corrected for 
multiple comparisons using Holm-Bonferroni method (Holm, 
1979). All calculations include error propagation.
RESULTS
Ketone Bodies Secretion
To determine the contribution of C8:0 and C10:0 to the release 
of ketone bodies, butyrate, and HMG in the medium, mass 
isotopomers, namely βHB (C0, C2, C4), AcAc (C0, C2, C4), 
HMG (C0, C1, C2), and butyrate (C2, C3, C4), were quantified 
over time. The release rates were calculated by linear fitting 
of these extracellular concentration profiles (total  =  labeled + 
unlabeled) and the areas under the curve (AUC) of the total 
concentrations were determined (Figure 1B). In particular, a 
significant (p  <  0.001) decrease in secretion rates and AUC of 
total βHB, total AcAc, and total butyrate was observed in the 
C10:0 experiment as compared to the C8:0. Noticeably, there 
was a different time delay of ketone secretion between the 
C8:0 and C10:0 condition. In the C8:0 experiment, secretion 
of βHB, AcAc, and butyrate was detected at time 30, 120, and 
30 min, respectively, while in the C10:0 condition, it was detected 
at time 60, 240, and 120  min, respectively (Figure 1C). These 
results indicate that both the rates of secretion and the total 
amounts of produced ketone bodies and butyrate are higher 
when astrocytes metabolize C8:0 compared to C10:0. No difference 
in total HMG secretion rate and AUC were measured.
Separation of the data into concentrations of mass 
isotopomers is shown in Figures 1C,D. In particular, in the 
case of AcAc a decrease (p  <  0.001) in both AUC and 
secretion rates were measured in the unlabeled and fully 
labeled fractions of the C10:0 as compared to the C8:0 
experiment. The secretion rate of AcAc C2 was also significantly 
lower (p  <  0.001) in the C10:0 condition as compared to 
the C8:0. The secretion rates and AUC of βHB C2 and βHB 
C4 were also significantly different according to the MCFA 
under investigation. A significant decrease of βHB C4 secretion 
rate (p  <  0.001) and AUC (p  <  0.001) was detected in the 
C10:0 condition as compared to the C8:0. The opposite was 
found for βHB C2 secretion rate (p  <  0.001) and AUC 
(p  <  0.01). No significant difference was measured in the 
AUC of the different mass isotopomers of HMG. However, 
the secretion rate of HMG C2 was significantly (p  <  0.01) 
higher in the C10:0 condition as compared to C8:0. Regarding 
butyrate, larger (p  <  0.001) secretion rates and AUC were 
identified in C3 and C4  in the C8:0 condition as compared 
to the C10:0. Finally, the unlabeled/(unlabeled + labeled) 
ratio at 360  min of βHB and AcAc was 51 and 71%, 83 and 
93%, for C8:0 and C10:0, respectively.
Biochemical Pathway Analysis in silico of 
C8:0-C10:0 Metabolism
To further investigate the observed differences between the 
impact of C8:0 and C10:0, biochemical pathway analysis in silico 
was employed to parse the known C8:0-C10:0 biochemical 
transformation space to identify downstream metabolites for 
measurement and flux modeling.
In the case of the C8:0 to βHB transformation space, 
we  identified 73 paths (minimum length 10, maximum length 
20), involving 84 unique metabolites interconnected by 91 
unique reactions (Figure 2A), considering the overall human 
metabolism. Similarly, in the case of the C10:0 to βHB 
transformation space, we  identified 67 paths (minimum length 
10, maximum length 20), involving 82 unique metabolites 
interconnected by 89 unique reactions (Figure 2B). Upon 
imposing astrocyte specificity (Özcan and Çakır, 2016), this 
transformation space was reduced to 33 metabolites and 37 
reactions in the case of C8:0-βHB (Figure 2A), and 47 metabolites 
and 56 reactions in the case of C10:0-βHB (Figure 2B). These 
filtered paths were used as the biochemical transformation 
space for analysis of C8:0 and C10:0 metabolism, and formulation 
of flux models (sub-networks). On one hand, these paths 
showed complete paths from C8:0-C10:0 to βHB, highlighting 
key intermediates (e.g., AcCoA, AcAc, and HMG). On the 
other hand, they also highlighted astrocyte-specific metabolic 
intermediates of C8:0-C10:0 degradation, wherein carbon 
introduced as C8:0-C10:0 could accumulate without being 
transformed to target compound formation (e.g., βHB and 
butyrate) (Figures 2A,B). Note that due to database limitation 
in terms of bound forms, the resulting metabolites are often 
only documented in the acyl-carrier protein (ACP)-bound form 
(wherever available). The purpose of Figure 2 is to provide 
the global network of MCFA metabolism.
Modeling of the Experimental  
13C-Labeled Curves
The mathematical model of β-oxidation to the production of 
βHB (Figure 3) used to fit the 13C isotopomer FE curves was 
based on Figure 2 and restricted to the detection of the mass 
isotopomers of the MCFA intermediates by LC-MS. In particular, 
only the fully labeled and fully unlabeled parts of the MCFA 
intermediates could be  detected in both intracellular and 
Sonnay et al. Metabolism of MCFA in Astrocytes
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extracellular space. Only unlabeled hexanoic acid (C6:0) was 
detected intracellularly, while both fully labeled and fully 
unlabeled fractions could be  measured extracellularly. None 
of the mass isotopomer of butyrate could be  detected 
intracellularly (presumably because the volatile butyric acid 
evaporated during extraction (solvent removal) under vacuum), 
while butyrate C2, C3, and C4 were present in the medium. 
The unstable AcAc was also probably degraded during cell 
pellet extraction and was thus undetectable intracellularly, but 
AcAc C0, C2, and C4 were measured in the medium. Finally, 
only unlabeled βHB was detected in astrocytes, while βHB 
C0, C2, and C4 were measured extracellularly. The network 
included both degradation (top-down direction) and elongation 
(bottom-up direction) of MCFA. Only the MCFA free acids 
could be  detected in the LC-MS measurements, and therefore 
the reactions involving the acyl-CoA-bound forms were 
considered as a proxy for the sub-network involving the free 
acid forms (Figure 3). The free acid pool sizes, which remained 
constant over time, were measured by LC-MS, except the 
AcCoA that was assumed to be  0.027  μmol/mg prot (Amaral 
et  al., 2011). In the C8:0 experiment, the initial intracellular 
concentrations of C8:0, 3-OH-C8:0, C6:0 and 3-OH-C6:0 were 
0.100  ±  0.056  μmol/g prot, 0.008  ±  0.004  μmol/g prot, 
0.060  ±  0.035  μmol/g prot, and 0.002  ±  0.001  μmol/g prot, 
respectively. In the C10:0 experiment, the initial intracellular 
concentrations of C10:0, 3-OH-C10:0, C8:0, 3-OH-C8:0, C6:0, 
and 3-OH-C6:0 were 0.156  ±  0.066  μmol/g prot, 
0.003  ±  0.001  μmol/g prot, 0.131  ±  0.072  μmol/g prot, 
0.008  ±  0.004  μmol/g prot, 0.048  ±  0.038  μmol/g prot, and 
0.002  ±  0.001  μmol/g prot, respectively.
The net transmembrane rates were fixed to the values 
determined from the measurements of the MCFA intermediate 
(F3, F5inv for C10:0, F7, F9, F11 for C8:0 and C10:0) and βHB 
(F14) total concentrations in the medium over time for each 
condition. Only the transmembrane exchanges (F1 and F1inv 
for C10:0 and F5 and F5inv for C8:0) at the level of the initial 
substrate were let to adjust and considered reversible to allow 
equilibration with the medium. F2, F6 and F10 convert the 
MCFA intermediates into their hydroxy-(3-OH) counterparts 
(F2inv, F6inv and F10inv are responsible for the reverse reactions). 
In those reactions, the carbon positions and numbers are 
maintained. In F4, F8 and F12 reactions carbons are lost (or 
gained in the case of the reverse reactions) in AcCoA and 
the resulting molecules are two carbons (F4 and F8) or four 
carbon (F12) shorter. The network applied to the C8:0 data 
is shown in grey in Figure 3. It was extended (in red) to 
the C10:0 data. Although labeled 3-OH-C10:0 and C10:0 
was detected in the medium (Figure 4), this extended model 
was not applied to the C8:0 data, because no labeled 3-OH-
C10:0 could be detected intracellularly and FE of intracellular 
C10:0 was associated with large SD (FE  <  1%). A dilution 
flux at the level of AcCoA (F13) was added to take into 
account potential utilization of unlabeled substrates present 
in the medium, namely glucose (Zwingmann and Leibfritz, 
2003) and amino acids (i.e., isoleucine and leucine) 
(Bixel and Hamprecht, 1995; Dienel and Cruz, 2009).
A
B
FIGURE 2 | Biochemical transformation space of (A) C8:0-βHB and (B) C10:0-βHB, starting from C8:0 or C10:0 on the left (green node) to βHB on the right 
(orange nodes). Additional nodes in purple indicate intermediate metabolites, while lines indicate chemical transformation-based connections between metabolites. 
Grey nodes indicate alternate intermediates not implicated in astrocytes based on genome scale metabolic model. Red lines indicate complete paths of 
transformation of C8:0 or C10:0 to βHB in astrocytes. Green lines ending with blue nodes indicate incomplete paths of C8:0 or C10:0 metabolism in astrocytes 
leading to carbons routing away from βHB. ACP, Acyl-carrier protein.
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Fluxes of β-Oxidation to Ketone  
Bodies Secretion
Significantly higher (p < 0.001) secretion rates of total 3-OH-C10:0 
(F3C8  =  0.0048  ±  0.0004  μmol/g prot/min vs. F3C10  = 
0.0079  ±  0.0004  μmol/g prot/min) and total C6:0 (F9C8  = 
0.093 ± 0.004 μmol/g prot/min vs. F9C10 = 0.118 ± 0.005 μmol/g 
prot/min) were measured in the C10:0 condition as compared 
to the C8:0. Higher contribution (p  <  0.001) of fully labeled 
carbons were measured in both 3-OH-C10:0 and C6:0 under 
C10:0 as compared to C8:0. On the contrary, the contribution 
of unlabeled carbons in 3-OH-C10:0 was higher (p  <  0.001) 
in the C8:0 experiment as compared to C10:0. Reversely, 
higher  (p  <  0.001) secretion rates of total 3-OH-C8:0 (F7C8  = 
0.0414  ±  0.0016  μmol/g prot/min vs. F7C10  = 0.0051  ± 
0.0003 μmol/g prot/min) and total 3-OH-C6:0 (F11C8 = 0.0079 ± 
0.0003  μmol/g prot/min vs. F11C10  =  0.0013  ±  0.0001  μmol/g 
prot/min) were measured in the case of C8:0 as compared to 
C10:0. The contribution of both fully labeled and unlabeled 
carbons were higher (p  <  0.001) in the C8:0 experiment as 
compared to the C10:0 (Figure 4).
The model generally mimicked the measured labeling 
curves in both C8:0 (R2  =  0.972) and C10:0 (R2  =  0.987) 
conditions (Figure 5). Supplementary Table S1 summarizes 
the fluxes computably determined and the calculated 
flux differences.
Effect of Medium-Chain Fatty Acids on 
Other Metabolic Pathways
To further investigate the antioxidant properties of C8:0 and 
C10:0, intracellular unlabeled concentrations of glutathione 
(reduced form) were measured over time. Significant (p < 0.05) 
higher concentration after 360  min was found in the C10:0 
experiment as compared to the C8:0 (Figure 6A). No labeled 
glutathione was detected.
FIGURE 3 | Mathematical model of β-oxidation (and elongation–reverse fluxes)—sub-network—to the production of βHB used to fit the 13C isotopomer FE curves. 
The model used to fit the C8:0 and C10:0 data is shown in grey, and in grey and red, respectively. The free acids were detected by LC-MS, while the acyl-CoA-
bound forms were not. Therefore, the acyl-CoA part was considered as a proxy for the free acid part. F3, F5inv (in the case of C10:0), F7, F9, F11 and F14 (in the case  
of C8:0 and C10:0) were fixed to the extracellular concentrations experimentally measured. F1, F1inv (for C10:0) and F5, F5inv (for C8:0) were let to adjust in the 
modeling process.
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A B
FIGURE 4 | (A) Changes in extracellular concentration over time of unlabeled (C0), fully labeled and total (unlabeled + fully labeled) MCFA intermediates measured 
in the C8:0 (on the left) and in the C10:0 (on the right) experiments. (B) Depicts the secretion rates and the AUC of total, unlabeled and fully labeled MCFA 
intermediates. Fully labeled C8:0 in the C8:0 experiment and C10:0 in the C10:0 experiment are not shown, because they are the incubation substrates.
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FIGURE 5 | Metabolic flux pathways for C8:0 and C10:0. On the left, 13C isotopomer FE curves and best fit of the mathematical model. On the right, linear 
regression of the extracellular concentrations experimentally measured and used to fix the transmembrane fluxes. The bar graphs represent the fluxes resulting from 
the model best fit. Each flux is shown with its associated SD.
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DISCUSSION
Although MCT-based ketogenic diets have received growing 
interest during the past few years, metabolism of C8:0 and 
C10:0 remains unclear. Thus, understanding the kinetics of 
βHB production and β-oxidation from MCFA would allow us 
to better define the rationale for optimal ketogenic composition 
to not only better provide ketones in the brain but also take 
advantage of other metabolic properties to reach specific health 
benefits. Based on the differences observed on the redox ratio 
produced by the oxidation of C8:0 and C10:0 (Thevenet et  al., 
2016), and on the fact that administration of higher level 
MCT did not have a significant impact on the concentration 
of ketone bodies in the brain of TBI patients, as compared 
to a standard formula (Bernini et  al., 2018), we  aimed at 
tracking the basal production of βHB from C8:0 and C10:0 
at the cellular level using metabolic flux analysis with 13C-labeled 
substrates. In this regard, we  conducted an integrative analysis 
in silico of ketometabolism in astrocytes, as well as experimental 
analysis using [U-13C]-C8:0 and [U-13C]-C10:0. Overall, this 
study demonstrates that the metabolic pathways underlying 
the β-oxidation of MCFA of different lengths, namely C8:0 
and C10:0, to the production of ketone bodies differ in human 
iPSC astrocytes. This differences stand not only in the total 
amount and mass isotopomers of MCFA intermediates and 
ketone bodies that are secreted, but also in the intracellular fluxes.
We observed that astrocytes incubated with C8:0 secreted 
more ketone bodies, namely βHB and AcAc, as well as butyrate, 
both in terms of production rates and total concentrations, 
compared to C10:0. Interestingly, most of the ketone bodies 
production arose from unlabeled sources present in the medium, 
suggesting that iPSC astrocytes do not exclusively require MCFA 
to produce βHB. This observation could in part explain the lack 
of increase in ketone bodies recently measured in TBI patients 
(Bernini et  al., 2018). The larger extracellular concentration of 
βHB found in the case of C8:0 is in line with our previous 
report, in which unlabeled C8:0 stimulated ketogenesis, as 
compared to unlabeled C10:0 and control (Thevenet et  al., 
2016). Furthermore, in the same study, extracellular βHB levels 
were similar in C10:0 and control experiments, indicating that 
iPSC astrocytes have the ability to produce βHB in the absence 
of MCFA (Thevenet et al., 2016). In addition, more fully labeled 
βHB (βHB C4) was produced under C8:0, while more partially 
labeled βHB (βHB C2) was secreted under C10:0. As the 
concentration of unlabeled βHB was similar between the two 
conditions (Figure 1D), the larger production of βHB in the 
case of C8:0 came from βHB C4 (Figures 1B–D). The secretion 
profile of AcAc, the precursor of βHB (Figure 6B) (Kanehisa 
and Goto, 2000; Kanehisa et  al., 2016, 2017), was different to 
the one of βHB. In particular, while C8:0 produced more AcAc 
C4 than C10:0, data also suggested that C8:0 increased the 
production of unlabeled AcAc from other unlabeled sources 
(Figures 1B–D). Additionally, the total amount (AUC) of AcAc 
C2 produced by the end of the experiment was the same for 
C8:0 and C10:0 experiments. To understand the relationship 
between AcAc and βHB, it may be  relevant to take HMG into 
consideration. HMG arises from the combination of a two-carbon 
molecule (AcCoA) and a four-carbon molecule (AcAc). Yet, 
no HMG C4 was detected in the medium and no difference 
in total and unlabeled production of HMG between C8:0 and 
C10:0 could be measured. Under the assumption that an enzyme 
should catalyze a reaction (in terms of rate) unreceptively of the 
labeling counterparts, these results indicate possible cellular 
compartmentalization of ketone bodies production.
Butyrate is downstream of 3-OH-C6:0, and in terms of 
carbon flow from C8:0-C10:0 to βHB in astrocytes, it can 
be  considered as a “carbon sink” (Figure 2). While significant 
labeled amount was measured in the medium, unlabeled butyrate 
was not present, suggesting that the production of butyrate 
is specific to the labeled substrates. Astrocytes treated with 
C8:0 secreted more butyrate C4 as compared to C10:0, in 
line with larger release and intracellular FE of fully labeled 
3-OH-C6:0. The production of butyrate C2 was, on the other 
hand, larger in the case of C10:0 than C8:0, and could arise 
from scrambling of AcCoA C2 with unlabeled 3-OH-C6:0. 
The fact that no C2-labeled MCFA and no unlabeled butyrate 
was detected indicate different production rate and possible 
cellular compartmentalization. While it is recognized that 
MCFA undergo β-oxidation in mitochondria, very long chain 
fatty acids (of length of 24 or higher) are oxidized in peroxisomes 
A B
FIGURE 6 | (A) Intracellular concentrations of unlabeled glutathione (reduced form) experimentally measured over time. (B) KEGG-based schematic overview of 
ketone bodies (i.e., AcAc, HMG and βHB) production from AcCoA.*p < 0.05.
Sonnay et al. Metabolism of MCFA in Astrocytes
Frontiers in Physiology | www.frontiersin.org 11 June 2019 | Volume 10 | Article 657
with hexanoyl as a final product (Wanders et  al., 2001). It 
was moreover reported that MCFA can be  synthetize both in 
the cytosol by the fatty acid synthase complex (Volpe and 
Kishimoto, 1972; Angeles and Hudkins, 2016) (KEGG database) 
and in mitochondria (reversal of β-oxidation) (KEGG database) 
(Hinsch et  al., 1976; Murad and Kishimoto, 1978).
In the description of the FE curves, we  included a dilution 
flux at the level of AcCoA, which not only reflects the production 
of unlabeled ketone bodies, but is also necessary to explain 
the important contribution of unlabeled carbons in the FE 
curves of the MCFA intermediates. The elongation fluxes (from 
AcCoA to MCFA production) were included based on the 
mass isotopomer contribution of unlabeled carbons and on 
the detection of labeled C10:0 and 3-OH-C10:0  in the medium 
of C8:0-incubated astrocytes (Figure 4). However, the latter 
was not included in the C8:0 experiment, because intracellular 
3-OH-C10:0 and C10:0 were not detectable and associated 
with high uncertainty, respectively, and therefore could not 
be  fitted by the model.
Analysis of the fluxes obtained with the mathematical model 
indicated opposite direction of metabolic flux at specific steps 
(i.e., F6-F6inv and F8-F8inv), suggesting different C8:0 and C10:0 
β-oxidation pathways. In particular in the C8:0 experiment, 
F6-F6inv and F8-F8inv are directed toward the production of βHB 
consistent with larger production of βHB C4 and AcAc C4. 
In the case of C10:0, unlike C8:0, the fraction of labeled carbons 
drastically decreased at the level of C8:0 (about 5% at 360 min) 
and stayed stable thereafter (i.e., in 3-OH-C8:0 and 3-OH-
C6:0), suggesting that an important carbon flow from unlabeled 
sources (F13) at the level of AcCoA must occur and contribute 
to the upstream pools (notably through F8inv and F6inv). As a 
result, even if both C8:0- and C10:0-treated astrocytes rely on 
significant contribution of unlabeled substrates, a larger dilution 
occurs in the case of C10:0. Amaral et  al. calculated that the 
consumption rate of isoleucine and leucine are about 10 times 
smaller than for glucose (Amaral et  al., 2011), in line with 
the general observation that glucose is the main energy substrate 
for the brain cells including astrocytes (Zwingmann and Leibfritz, 
2003; Thevenet et  al., 2016). Therefore, it seems reasonable to 
attribute the dilution at the level of AcCoA (F13) to glucose. 
In fact, as reported in our previous study (Thevenet et  al., 
2016), the large lactate/βHB ratio secretion rate and the 
unchanged ATP levels when inhibiting mitochondrial ATP 
synthesis indicate that glucose remains the main energy 
substrate in our experimental conditions even in the presence 
of MCFA. Interestingly, reduced glycolysis and decrease 
phosphofructokinase activity in the case of C8:0 was reported 
by Tan et  al. (2017), and larger lactate release upon C10:0 as 
compared to C8:0 was measured by Thevenet et  al. (2016). 
F13 was estimated to be  0.187  ±  0.017  μmol/g prot/min and 
0.490 ± 0.045 μmol/g prot/min in the C8:0 and C10:0 experiment, 
respectively, which is in line with these previous reports 
(Thevenet et  al., 2016; Tan et  al., 2017).
While the secretion of ketone bodies comprised mostly of 
the unlabeled fractions, larger amounts of labeled than unlabeled 
MCFA intermediates were secreted (Figure 4). Moreover, the 
extracellular secretion profile of the MCFA intermediates was 
different in the C8:0 and C10:0 experiments. In the case of 
C8:0, labels were mostly secreted as hydroxy-(3-OH) molecules, 
except for 3-OH-C10:0 that was secreted in a larger extent in 
the C10:0 condition. The opposite direction of metabolic flux 
estimated in the present study suggests different C8:0 and 
C10:0 β-oxidation pathways, and potential modulation when 
both MCFA are simultaneously provided (Khabbush et  al., 
2017). These observations support our hypothesis that C8:0 
and C10:0 could exhibit different biological functions due to 
their different metabolism, and that their beneficial effects may 
not be  limited to production of ketones. Interestingly, 3-OH-
C10:0 was shown to depolarize the squid giant axon in inhibiting 
the sodium channels (Takenaka et  al., 1981) and C10:0 was 
reported to be  more anticonvulsant than C8:0 (Chang et  al., 
2016; Tan et  al., 2017). In addition to the direct inhibition 
of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors (Chang et  al., 2016), we  speculate that this 
additional anti-seizure effect could be  due to production of 
3-OH-C10:0; however, this requires further investigation. We, 
moreover, observed that secretion of C6:0 was higher in C10:0 
as compared to C8:0. Although the function of C6:0 is unclear, 
it is worth mentioning that C6:0 was shown to contribute to 
energy metabolism (Ishiwata et  al., 1996), as well as to induce 
neurite growth (Kamata et al., 2007). All together, these results 
point to different metabolic network activation and biological 
functions depending on the carbon length of the substrate. 
This suggests that the underlying enzymes are substrate-specific, 
preferentially catalyzing molecules of specific chain lengths 
and/or adapting to the requirements of specific cellular states, 
potentially impacting differently the cellular environment.
Finally, an increase in intracellular unlabeled glutathione 
concentration was observed over time. This increase was 
significantly higher by the end of the experiment in the C10:0 
condition, indicating potential benefits of C10:0 as compared 
to C8:0  in terms of antioxidant properties. This observation 
is consistent with the earlier findings of increased brain reduced 
glutathione levels in rats given C10:0-enriched oil (Sengupa 
and Ghosh, 2012) and higher expression of genes regulating 
the expression of antioxidant enzymes in the hippocampus of 
mice fed with C10:0 as compared to C8:0 (Tan et  al., 2017), 
suggesting therefore potential beneficial effects related to C10:0. 
Although further experiments are needed to further assess the 
link between glutathione and C10:0, it is noteworthy that C10:0 
is an agonist of the peroxisome proliferator-activated receptor 
(PPAR) α (Malapaka et  al., 2012) involved in glutathione level 
modulation (Abdelmegeed et  al., 2009).
In conclusion, while C8:0 and C10:0 appear structurally 
similar, as they differ in length by only two carbons, the 
metabolic pathways underlying their metabolism are different 
in human iPSC astrocytes. In particular, flux analysis indicate 
opposite direction of metabolic flux at specific steps, with an 
important fraction of unlabeled sources contributing to the 
elongation steps in the case of C10:0, suggesting different C8:0 
and C10:0 β-oxidation pathways. The total extracellular 
concentrations and secretion rates of βHB, AcAc and butyrate 
are higher and faster, respectively, in the case of C8:0, 
while intracellular glutathione formation and secretions of 
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3-OH-C10:0 and C6:0 were larger with C10:0. Overall, the 
findings suggest MCFA-specific ketometabolic traits, which 
could be  of interest for personalized nutritional intervention 
and the design of optimal ketogenic diet supplementation. 
Further studies involving different ratios of C8:0/C10:0  in 
appropriate models of glucose metabolism impairment are 
required to investigate sustainable and targeted ketone production, 
with optimal antioxidant and anticonvulsant impacts.
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